Background {#Sec1}
==========

Total knee arthroplasty (TKA) is recommended as an effective method for end-stage knee osteoarthritis or rheumatoid arthritis \[[@CR1]\]. However, it may cause severe blood loss during the perioperative period. Tranexamic acid (TXA) is one of most important antifibrinolytic agents and is known to reduce blood loss, hemoglobin (Hb) drop, and blood transfusion \[[@CR2]--[@CR4]\]. While many meta-analyses and randomized controlled trials (RCTs) have focused on the efficacy of intravenous and topical TXA on TKA \[[@CR5]--[@CR7]\], few have demonstrated the safety and efficacy of oral administration \[[@CR3], [@CR8], [@CR9]\]. While drug allergic reaction of anaphylactic shock have been reported in intravenous administration \[[@CR10]\], topical administration has a risk of periprosthetic contamination due to infected needles that may cause septicopyemia \[[@CR11]\]; in addition, the short duration of the topical form of the drug limits its application \[[@CR11], [@CR12]\]. Because oral TXA is administered gradually, a number of RCTs or retrospective controlled studies (RCSs) have been performed to investigate its efficacy and side effects \[[@CR13]--[@CR15]\]. Oral TXA application undergoes rapid and large absorption. Furthermore, it is easy to use without special equipment compared to intravenous or topical injection, is less costly, and offers a less burdensome workload for medical personnel \[[@CR16]\]. No conclusive evidence has been found regarding the efficacy of using oral TXA during the perioperative period in TKA. The purpose of this meta-analysis was to determine the blood-sparing efficacy of oral TXA administration in TKA.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

We systemically searched randomized controlled trials or retrospective cohort studies, including PubMed (1996--April 2017), Embase (1980--April 2017), and the Cochrane Library (CENTRAL, April 2017). Trials were also found in related references of additional studies. Only English publications were included in our meta-analysis. The search terms "total knee arthroplasty," "total knee replacement," "oral tranexamic acid," and "oral TXA" were used as keywords with Boolean operators "AND" or "OR." The search results are presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1The search results and selection procedure

Inclusion criteria {#Sec4}
------------------

Studies were eligible for the meta-analysis if they met the following PICOS (participants, intervention, comparison, outcomes, and study design) criteria: (1) participants: patients who received TKA for the first time; (2) intervention: oral administration of TXA; (3) comparison: non-TXA applied to TKA; (4) outcomes: hemoglobin drop, blood loss, transfusion rate, complications, and length of hospital stay; (5) study design: randomized controlled trials or retrospective cohort studies.

Data extraction and quality assessment {#Sec5}
--------------------------------------

A standard data entry form was designed for the data extraction. Two reviewers independently extracted the available study data. The extracted data included author(s), patients (*n*), publication date, age, gender, study design, body mass index, and dose of TXA. The primary outcomes were Hb drop and blood loss. The secondary outcomes consisted of the transfusion rate, length of hospital stay, and complications. We emailed the corresponding authors of studies with incomplete or graphical data. Any disagreement between two reviewers was solved by a third reviewer. The Jadad scale was used to evaluate the risk of bias for RCTs, which consisted of random sequence generation, allocation concealment, the blinding of participants and personnel, incomplete outcome data, selective reporting, and other biases \[[@CR17], [@CR18]\]. The study was considered high quality if the Jadad score was more than 4 points. For non-RCTs, the risk of bias was evaluated using the Newcastle-Ottawa scale \[[@CR19]\], and a score of more than 5 points was considered high quality.

Data synthesis {#Sec6}
--------------

Outcomes were calculated using Windows Review Manager Software 5.3 (The Nordic Cochrane Center, The Collaboration, 2014, Copenhagen, Denmark). For continuous outcomes, we used mean difference (MD) with 95% confidence intervals (CIs) to weigh the effect interval. For noncontinuous outcomes, relative risk (RR), odds ratio (OR), or risk difference (RD) with 95% CIs were used to weigh the effect interval. The statistical heterogeneity was judged by the value of *P* and *I* ^2^ using the standard chi-squared test. *I* ^2^ \> 50% and *P* \< 0.1 were considered statistically significant in our results, and a random-effect model was applied for assessment; otherwise, a fixed-effect model was used for extracted data.

Subgroup analysis {#Sec7}
-----------------

When the data had high heterogeneity, we used the random-effect model to ensure the outcome was reliable and accurate, and we performed a subgroup analysis to investigate the causes of heterogeneity. Even when the random-effect model and subgroup analysis were used to decrease the heterogeneity, there was inevitable heterogeneity in the study design and the dose of oral administration, among other factors.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

A total of 224 studies were identified through the search strategy. Thirty-four studies were excluded by Endnote software. Overall, 178 studies were excluded due to the title and abstract. According to the inclusion criteria, 6 studies were included by reading the full text: 5 were RCTs \[[@CR14], [@CR15], [@CR20]--[@CR22]\] and 1 was an RCS \[[@CR13]\]. The baseline characteristics of the included studies are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1The characteristics of included studiesOral TXA group/control groupStudies (year)CountryCasesAges (year)Female gender (%)Preoperative Hb (g/dL)BMI (kg/m^2^)Reference typePreoperative diagnosePreoperative thromboembolic eventsPreoperative clotting disorder or anticoagulant therapyQASLee et al. (2017) \[[@CR15]\]China94/9570/6867/69.5513.6 ± 1.3/13.8 ± 1.227.7/28.4RCTN/ANoneNone6Yuan et al. (2017) \[[@CR14]\]China140/4063.2/64.651.4/53.513.2 ± 0.8/13.2 ± 0.822.69/22.68RCTOA or RAN/ANone6Perreault et al. (2017) \[[@CR13]\]USA1049/86666.1/66.262.4/58.214 ± 1.4/14 ± 1.4N/ARCSN/ANoneN/A6Zohar et al. (2004) \[[@CR21]\]Israel20/2069/7360/65N/AN/ARCTN/AN/ANone5Alipour et al. (2013) \[[@CR22]\]Iran27/2668.6/63.1159.3/56.7N/A28.9/29.3RCTOA or RANoneNone6Bradshaw et al. (2012) \[[@CR20]\]Australia26/2067.1/68.246.2/3513.4 ± 2.5/13.8 ± 332.4/32.5RCTOANoneNone6*TXA* tranexamic acid, *Hb* hemoglobin, *BMI* body mass index, *QAS* quality assessment score, *RCT* randomized controlled trial, *RCS* retrospective cohort study, *N/A* not applicable, *USA* the United States of America, *OA* osteoarthritis, *RA* rheumatoid arthritis Table 2Characteristics of included studies showing general intervention informationStudies (year)Dosage of TXA (mg)Surgical approachTransfusion criteriaPostoperative anticoagulationSurgeryAnesthesiaDVT screening methodPneumatic tourniquetLee et al. (2017) \[[@CR15]\]3000MPHb \< 80 g/LN/APrimary TKAGeneral anesthesiaDoppler ultrasonographyYesYuan et al. (2017) \[[@CR14]\]N/AMPHb \< 80 g/L or anemia symptoms10 mg/day rivaroxabanPrimary TKAGeneral anesthesiaDoppler ultrasonography and chest computed tomographyYesPerreault et al. (2017) \[[@CR13]\]3900N/AHb \< 80 g/L or anemia symptomsN/APrimary TKAN/AN/AN/AZohar et al. (2004) \[[@CR21]\]3000N/AHematocrit \< 28%40 mg/day enoxaparinPrimary TKAN/ADoppler ultrasound imaging and signs of lower limb DVT(swelling or increase in calf diameter)YesAlipour et al. (2013) \[[@CR22]\]3000N/AN/A40 mg/day enoxaparinPrimary TKAStandard general anesthesiaN/AYesBradshaw et al. (2012) \[[@CR20]\]6000MPHb \< 70 g/L or anemia symptoms40 mg/day enoxaparinPrimary TKAN/AN/AYes*TXA* tranexamic acid, *N/A* not applicable, *Hb* hemoglobin, *MP* medial parapatellar approach, *DVT* deep vein thrombosis, *TKA* total knee arthroplasty

Study characteristics {#Sec10}
---------------------

### Risk of bias in included studies {#Sec11}

Publication bias was evaluated using a funnel plot diagram (Fig. [2](#Fig2){ref-type="fig"}). The funnel plot diagram of Hb drops, blood loss, transfusion rate, length of hospital stay, and complications was symmetrical, indicating a low risk of publication bias.Fig. 2**a** A funnel plot of the Hb drop. **b** A funnel plot of the blood loss. **c** A funnel plot of the transfusion rate. **d** A funnel plot of the complications. **e** A funnel plot of the length of hospital stay

Meta-analysis results {#Sec12}
---------------------

### Hemoglobin drop {#Sec13}

Data from three studies including 2150 patients reported the Hb drops at the lowest postoperative Hb level during hospital stays. Compared to the control group, oral TXA significantly prevented Hb drop (MD = − 0.80; 95% CI, − 0.88, − 0.71; *P* \< 0.05; Fig. [3](#Fig3){ref-type="fig"}). The fixed-effect model was used to find the statistical heterogeneity between the two groups (*x* ^2^ = 0.17; df = 2; *P* = 0.92; *I* ^2^ = 0%; Fig. [3](#Fig3){ref-type="fig"}).Fig. 3A forest plot diagram showing the Hb drop (g/dL)

### Blood loss {#Sec14}

The blood loss 12 h after surgery was reported in two studies totaling 93 patients. No significant difference was found between the oral TXA and the control groups (MD = − 36.15; 95% CI, − 141.99, 69.68; *P* \> 0.05; Fig. [4](#Fig4){ref-type="fig"}). The blood loss 24 h after surgery was reported in two studies of 93 patients. Compared to the control groups, oral TXA significantly prevented blood loss 24 h after surgery (MD = − 144.66; 95% CI, − 201.56, − 87.76; *P* \< 0.05; Fig. [4](#Fig4){ref-type="fig"}). Data from two studies including 235 patients recorded the total blood loss. The oral TXA groups had significantly less blood loss compared to the control groups (MD = − 231.55; 95% CI, − 290.70, − 172.39; *P* \< 0.05; Fig. [4](#Fig4){ref-type="fig"}). Statistical heterogeneity was not found in blood loss 24 h after surgery (*x* ^2^ = 0.25; df = 1; *P* = 0.62; *I* ^2^ = 0%) or total blood loss (*x* ^2^ = 0.06; df = 1; *P* = 0.80; *I* ^2^ = 0%; Fig. [4](#Fig4){ref-type="fig"}). A random-effects model was applied in the study due to the statistical heterogeneity found in blood loss 12 h after surgery (*x* ^2^ = 3.28; df = 1; *P* = 0.07; *I* ^2^ = 69%; Fig. [4](#Fig4){ref-type="fig"}).Fig. 4A forest plot diagram showing the blood loss (mL)

### Transfusion rate {#Sec15}

The transfusion rate was reported in three studies including 2384 patients. Compared to the control groups, the oral TXA groups had significantly reduced transfusion rates (OR = 0.40; 95% CI, 0.30, 0.52; *P* \< 0.05; Fig. [5](#Fig5){ref-type="fig"}). A fixed-effect model was applied because no statistical heterogeneity was found in this meta-analysis (*x* ^2^ = 0.25; df = 2; *P* = 0.88; *I* ^2^ = 0%; Fig. [5](#Fig5){ref-type="fig"}).Fig. 5A forest plot diagram showing the transfusion rate (%)

### Complications {#Sec16}

We extracted data on complications including deep vein thrombosis (DVT) and pulmonary embolism (PE) from five studies including 465 patients. There was no significant difference between the oral TXA and the control groups (RD = − 0.01; 95% CI, − 0.04, 0.02; *P* \> 0.05; Fig. [6](#Fig6){ref-type="fig"}). Because of the low statistical heterogeneity, we used a fixed-effect model (*x* ^2^ = 4.51; df =4; *P* = 0.34; *I* ^2^ = 11%; Fig. [6](#Fig6){ref-type="fig"}).Fig. 6A forest plot diagram showing the complications (%)

### Length of hospital stay {#Sec17}

Length of hospital stay was reported in three studies involving 2144 patients. No significant difference was found between the two groups (MD = − 0.00; 95% CI, − 0.08, 0.08; *P* \> 0.05; Fig. [7](#Fig7){ref-type="fig"}). Because of the low statistical heterogeneity, we used a fixed-effect model (*x* ^2^ = 2.62; df = 2; *P* = 0.27; *I* ^2^ = 24%; Fig. [7](#Fig7){ref-type="fig"}).Fig. 7A forest plot diagram showing the length of hospital stay (days)

Discussion {#Sec18}
==========

Recently, attention has been paid to oral TXA due to its rapid absorption, operability, and less cost \[[@CR23], [@CR24]\]. Applicable management during the perioperative period reduces both the recovery time and the transfusion rate. TXA as one of the most important antifibrinolytics has shown strong effects on reducing blood loss by blocking the lysine-binding sites of plasminogen. The two methods of topical application and intravenous injection administration prevented significant blood loss \[[@CR25]--[@CR27]\]. Anaphylactic shock was reported in patients using intravenous injection, and there was also a potential risk of periprosthetic infection once the needle was contaminated \[[@CR11], [@CR12]\]. It has recently been reported that oral TXA has the same effects in preventing blood loss, Hb drop, and the transfusion rate compared to intravenous or topical administration \[[@CR28]\].

In our meta-analysis, all patients in the included studies had been diagnosed without preoperative coagulation disorders. Alipour et al. \[[@CR22]\] excluded from the study patients with thromboembolic events and those who had recently taken anticoagulants or non-steroidal anti-inflammatory drugs. Bradshaw et al. \[[@CR20]\] had exclusion criteria that included a history of thromboembolic events and/or anticoagulation that could not be ceased within the recommended time before surgery. Patients with thromboembolic diseases, anticoagulation, or DVT prophylaxis were excluded by Lee et al \[[@CR15]\]. Yuan et al. \[[@CR14]\] excluded patients with coagulopathy or bleeding disorders. Zohar et al. \[[@CR21]\] excluded patients with bleeding disorders or current anticoagulant therapy. Perreault et al. \[[@CR13]\] excluded patients with a history of pulmonary embolus or DVT. Three of the included studies recorded preoperative hemoglobin levels. Lee et al. \[[@CR15]\] reported preoperative Hb levels in the oral and control groups of 13.3 ± 1.3 g/dL and 13.8 ± 1.2 g/dL, respectively. Yuan et al. \[[@CR14]\] reported preoperative Hb levels of 13.2 ± 0.8 g/dL and 13.2 ± 0.8 g/dL, respectively, in the oral and control groups. Bradshaw et al. \[[@CR20]\] reported preoperative Hb levels of 13.4 ± 2.5 g/dL and 13.8 ± 3 g/dL in the oral and control groups, respectively. Perreault et al. \[[@CR13]\] reported preoperative Hb levels of 14.1 ± 1.4 g/dL in the oral group and 14 ± 1.4 g/dL in the control group.

Concerning the surgical approach, the medial parapatellar method was performed by Lee et al. \[[@CR15]\], Yuan et al. \[[@CR14]\], and Bradshaw et al. \[[@CR20]\]. Three of the included studies did not record the surgical methods \[[@CR13], [@CR21], [@CR22]\]. Bradshaw et al. \[[@CR20]\] reported that the indications for blood transfusion were hemoglobin levels of less than 7 g/dL or clinical symptoms of anemia. Lee et al. \[[@CR15]\] recorded that the serum Hb level for transfusion trigger was 8 g/dL. Yuan et al. \[[@CR14]\] showed that blood transfusions were performed following a restrictive strategy (Hb \< 8 g/dL) or symptoms of anemia. Zohar et al. \[[@CR21]\] reported that hematocrit \< 28% constituted the postoperative transfusion trigger. Perreault et al. \[[@CR13]\] settled on a predefined protocol, with transfusion of Hb \< 8 g/dL or Hb \< 10 g/dL in patients with significant symptoms of anemia.

Concerning the anticoagulation method, rivaroxaban (10 mg/day) was taken orally until 21 days after hospital discharge in Yuan et al.'s research \[[@CR14]\]. In Zohar et al.'s \[[@CR21]\] study, subcutaneous enoxaparin (40 mg/day) was administered for DVT prophylaxis. Alipour et al. \[[@CR22]\] reported that enoxaparin with a dose of 40 mg/day was prescribed from 1 day before surgery and maintained for 2 weeks. Bradshaw et al. \[[@CR20]\] reported that anticoagulation consisted of 40 mg/day of enoxaparin was administered for 2 weeks starting at 12 h postoperatively. Lee et al. \[[@CR15]\]reported all patients had Doppler ultrasonography on postoperative day 7 to detect any proximal DVT. In Zohar et al.'s \[[@CR21]\] trial, all patients were examined daily for signs of lower limb DVT (swelling or an increase in the calf diameter) and underwent lower limb Doppler ultrasound imaging on the fifth postoperative day.

Hb drop was the primary outcome in our meta-analysis. Several high-quality RCTs and RCSs showed that oral TXA can prevent Hb drop postoperatively \[[@CR13], [@CR15]\]. Perreault et al. \[[@CR13]\] found that there was less Hb drop in the oral TXA group compared to the untreated group. These results were consistent with our outcomes. Our pooled data demonstrated that oral TXA can prevent Hb drop postoperatively. Irwin et al. \[[@CR29]\] demonstrated that oral TXA provided similar effects on lower Hb drop compared to intravenous TXA. In conclusion, oral TXA can effectively inhibit Hb drop.

Blood loss was also an important indicator for evaluating blood sparing. An RCT reported by Bradshaw et al. \[[@CR20]\] showed that oral TXA prevented total blood loss significantly compared to the untreated group, and the same outcome was reported by Lee et al. \[[@CR15]\]. Our meta-analysis was consistent with these results. In our meta-analysis, oral TXA significantly reduced total blood loss compared to the control group. Two high-quality RCTs showed that oral TXA could limit blood loss 24 h after surgery \[[@CR21], [@CR22]\]. This is consistent with our findings. As to blood loss at 12 h after surgery, Zohar et al. \[[@CR21]\] reported that the amount of blood loss in the surgical drain was similar in the oral TXA group and the control group. This is also consistent with our findings. Our meta-analysis concluded that no significant differences were found between the oral TXA group and the control group. Meanwhile, risk of bias and high heterogeneity should be considered when interpreting the findings. We considered that the imbalance between fibrinolysis and TXA-induced antifibrinolytics is due to the release of tourniquet. Tourniquet release can accelerate fibrinolysis, while the optimal effects of oral TXA appeared 2 h after ingestion \[[@CR16], [@CR30]\]. As a consequence, the oral TXA group did not have inhibited fibrinolysis caused by tourniquet release. Therefore, no significant differences in blood loss were found in the oral and control TXA groups 12 h after surgery. However, because of the small sample size (under 100 patients), the conclusion with respect to blood loss was limited compared to the findings on Hb drop and transfusion rate.

The blood-sparing efficacy was also reflected in the transfusion rate. Perreault et al. \[[@CR13]\] used a large hospital database to assess the rate of transfusion among the oral TXA and control groups. The outcomes of this RCT demonstrated that the oral TXA group had a lower rate of transfusion compared to the control group. This is consistent with our findings. Lee et al. \[[@CR15]\] reported that there were no significant differences in transfusion rates between the two groups. The possible reason for low transfusion rate in both groups was the high postoperative Hb level compared to the transfusion trigger \[[@CR31]\]. Thus, we conclude that the oral TXA group has a lower transfusion rate compared to the control group. Postoperative DVT and PE were common complications in TKA patients who took TXA. Our meta-analysis failed to find any significant differences between the two groups. Similar findings were reported by Lee et al. \[[@CR15]\]. The results of our pooled data indicated that there were no differences in length of hospital stay because of the low incidence in both groups. Taking these findings together, we considered that there were no obvious differences in complications and length of hospital stay in the oral TXA group and the control group. Moreover, it has been reported that the cost of oral TXA administration was much lower compared to intravenous or topical forms \[[@CR14], [@CR32], [@CR33]\]. However, all patients of our included studies have been diagnosed without history of thromboembolic events or a higher thromboembolic risk, and there was less or even no data available dealing with the use of TXA with a higher thromboembolic risk. Taking these into consideration, it may potentially limit the general use of TXA in elective surgeries.

Several reports have demonstrated that oral TXA helps reduce hematocrit drop \[[@CR20], [@CR22]\]. Our meta-analysis did not analyze hematocrit drop for two reasons: because of the small sample of included studies, and the ratio between Hb drop and hematocrit drop is always supposed to be 1/3. Patients with potential malfunctioning coagulation systems such as hemophilia, unknown bleeding disorders, active liver disease, and so on usually cannot be detected without preoperative diagnostics during preoperative blood management, while malfunctioning coagulation system can potentially cause postoperative DVT \[[@CR34]\]. In our meta-analysis, Lee et al. \[[@CR15]\] excluded 46 patients who had potentially malfunctioning coagulation systems and a history of thromboembolic disease and other disease. Yuan et al. \[[@CR14]\] excluded three patients with clotting mechanism disorders throughout preoperative diagnostics. Remaining studies failed to carry out preoperative diagnostics on patients during preoperative blood management, which may increase the risk of thrombus.

Our meta-analysis and systematic review have several limitations: (1) Only five studies were included in our meta-analysis. The statistical results would be better if more RCTs had been included. (2) Outcomes such as hematocrit and cost were not analyzed due to the small sample size and/or insufficient data. (3) Only English publications were included in our meta-analysis, so there is publication bias. (4) Because of the significant heterogeneity of blood loss at 12 h (*I* ^2^ = 69%), we attempted to investigate the source of heterogeneity. Throughout the full articles, the administrations time of TXA before surgery were different (1 and 2 h before surgery, respectively) and the length of enoxaparin use showed large differences (1 and 14 days, respectively) in two studies. Considering the short half-life of oral TXA and the anticoagulant effect of enoxaparin, we believe these differences were the major sources of the heterogeneity. Meta-analyses (PRISMA) guidelines and the Cochrane Handbook were used to assess the quality of the data published in the included studies to ensure that the results of our meta-analysis were reliable and receivable.

Conclusions {#Sec19}
===========

Compared to the control group, Hb drop, blood loss, and transfusion rates can be significantly reduced using oral TXA without increasing the risk of complications. Moreover, oral administration is cheaper and easier to use compared to IV and topical applications. Nevertheless, oral TXA should be restricted to selected patients after adequate preoperative blood management and surgeries with extensive blood loss, as there is no current clear recommendation for the general use of TXA in elective orthopedic surgeries such as TKA.
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